Peginterferon for chronic hepatitis B in children
Treatments studied
Part of Digestive system, Infections clinical trials.
This study tests a medicine called peginterferon alfa-2b to see if it can help children with chronic hepatitis B achieve a functional cure, meaning the virus stays under control. If your child has hepatitis B, this treatment might improve their chances of clearing the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 3 and 17 years old.
- Your child must have a positive test for hepatitis B virus DNA.
- Your child must have a positive test for hepatitis B surface antigen (HBsAg).
- You and your child (if old enough) must agree to join the study and sign a consent form. If both parents are guardians, both must sign.
- Your child must not have other liver infections (like hepatitis A, C, D, E) or HIV.
- Your child must not have certain medical conditions that make it unsafe to take peginterferon, such as severe liver damage, autoimmune diseases, uncontrolled diabetes, or severe heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining peginterferon alpha-2b with a nucleoside analog can lower liver cancer risk in people with chronic hepatitis B who have a family history of liver cancer. It compares the combination therapy to nucleoside analog alone.
This study looks at how well antiviral medicines work in children with chronic hepatitis B. It may help doctors find better ways to treat children who are starting treatment or who have been on treatment for a while.
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This study looks at whether extra treatment with peginterferon (a drug that boosts the immune system) can help lower the amount of hidden hepatitis B virus in the liver after you've already reached clinical cure. You'll have two liver biopsies to measure this, and the findings may help prevent the virus from coming back.
Hear when a new HBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.